Beyond the Single SNP: Emerging Developments in Mendelian Randomization in the “Omics” Era by Brion, Marie-Jo A. et al.
 1 
SpringerLink Header: Genetic Epidemiology (J Witte, Section Editor) 
 
Beyond the Single SNP: Emerging Developments in Mendelian Randomization in the 
‘Omics’ Era 
Marie-Jo A Brion, PhD*
1, 2
, Beben Benyamin, PhD*
1
, 
Peter M Visscher, PhD
1,3
, George Davey Smith DSc
2
. 
 
* Joint first authorship 
1
 The University of Queensland, Queensland Brain Institute, QLD 4072 Australia 
2
 MRC Integrative Epidemiology Unit, University of Bristol, Bristol BS8 2BN 
3
 The University of Queensland Diamantina Institute, Princess Alexandra Hospital, QLD 4102, 
Australia. 
 
Marie-Jo Brion 
Address: Queensland Brain Institute, The University of Queensland, St Lucia, QLD 4072 
Australia. Phone: +61 7 334 66 429. Email: m.brion@uq.edu.au.  
Additional affiliations: MRC Integrative Epidemiology Unit, University of Bristol, Bristol BS8 
2BN 
 
Beben Benyamin [Corresponding author] 
Address: The University of Queensland, Queensland Brain Institute, QLD 4072 Australia 
Australia. Phone: +61 7 3346 6430. Email: b.benyamin@uq.edu.au 
 
Peter M Visscher 
Address: The University of Queensland, Queensland Brain Institute, QLD 4072 Australia. 
Phone: +61 7 3346 6348. Email: Peter.Visscher@uq.edu.au 
 
George Davey Smith 
Address: MRC Integrative Epidemiology Unit, University of Bristol, Bristol BS8 2BN 
Phone: +44 (0)117 3310099 Email: Julia.Mackay@bristol.ac.uk 
 
KEYWORDS: causality; DNA sequence; disease etiology; epidemiology; epigenetic; genetic; 
genome-wide; instrumental variable; Mendelian randomization; metabolomic; omics risk factors 
 
ABSTRACT 
Mendelian randomization (MR) is an innovative epidemiological approach, which uses genetic 
variants as proxies for environmental exposures to provide unbiased estimates of the causal 
effect of a risk factor on disease. The explosion in availability of high-throughput biological data 
have resulted in increasing numbers of MR studies, novel extensions to the traditional single-
SNP MR approach and the potential to incorporate new generation biological “omics” data (such 
as genome-wide genotype data, epigenetics and metabolomic data). In this review, we discuss 
these new developments, ranging from the application of multiple genetic markers and the use of 
summary statistic data, through to MR approaches in the “omics” age. Progress in “omics” 
technologies has been touted with the ability to revolutionize epidemiology and the incorporation 
of “omics” data into MR, to infer causality of potentially large numbers of novel biological 
markers, reflects one avenue of how this may be realized.  
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INTRODUCTION 
Mendelian Randomization (MR) is an epidemiological method that uses genetic variants to 
estimate the causal effect of risk factors on disease-related outcomes from observational data (1–
7). It is aimed at overcoming problems with confounding that typically limit observational 
association studies. The tendency for observational studies to incorrectly identify causal risk 
factors has been highlighted by a number of cases. For example, apparently robust observational 
associations of Vitamin E with cardiovascular disease, beta-carotene with cancer, and estrogen 
with Alzheimer’s disease reported by such studies were not supported by subsequent randomized 
control trials (RCTs) (1,8). Incomplete control for confounders in the observational studies is 
likely to be a key reason for this discrepancy in findings (9). This has led to strong 
epidemiological interest in pursuing approaches, such as MR, which can strengthen causal 
inference (10).  
 
In MR, a genetic variant acts as an instrumental variable (IV) or proxy for an exposure of interest 
that is postulated to influence a disease-related outcome.  The causal effect of an exposure on a 
disease outcome is estimated from the association of the genetic instrument with the outcome, 
taking into account the genetic variant’s association with the exposure (See Figure 1). Based on 
Mendel’s laws of inheritance, i.e. (i) alleles segregate at conception independent of environment, 
(ii) genetic variants affecting different trait can sort independently, associations between genetic 
instruments and outcomes are not generally confounded by behavioral or environmental 
exposures at the population level (1,6). These provide a framework that mimics an RCT to infer 
causality between an exposure and a disease outcome. 
 
There are, however, a number of known limitations (1,11–14). In particular, MR requires a 
number of strong assumptions to be met. Beyond the genetic variant’s association with the 
exposure trait, there must be no unmeasured common causes of the genetic variant and the 
outcome. The outcome must not also be associated with the genetic variant, except through its 
association with the exposure variable. Population stratification (i.e. when population subgroups 
differ both in disease rates and allele frequencies for variants of interest) is the most likely 
unmeasured common cause of both genetic variation and the outcome.  In addition, since a single 
genetic variant generally explains only a small amount of variation in a trait of interest, low 
statistical power is frequently an issue for MR studies as its power is positively correlated with 
the amount of phenotypic variance explained by the genetic variant(s) (1,15). Finally, there is 
also the possibility of confounding being re-introduced through linkage disequilibrium (LD, 
correlation among SNPs) or pleiotropy (where a genetic variant has multiple functional 
consequences). This topic has been discussed in more detail elsewhere (16). 
 
Despite these limitations, MR studies have already yielded many clinically relevant findings, 
providing evidence regarding causality for a range of risk factors on disease outcomes (see Table 
1). Indeed, MR has been hailed as an approach that stands to make major contributions to 
understanding aetiological pathways in complex disease (2). With the recent methodological 
advances and the explosion in biological data being generated, particularly from high throughput 
technologies and the successes of GWAS, the range of biomedical questions that can be tested 
using MR promises to broaden even further. 
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In this review, we firstly discuss the recent developments in MR, covering new approaches that 
incorporate a range of information and hypotheses that could potentially address a number of its 
existing limitations. Secondly, we explore how the original MR approach can be extended to 
incorporate the increasingly available “omics” data, such as genome-wide genotype data, 
epigenetics and metabolomic data, to increase our understanding of new biological pathways and 
their potential roles in disease etiology. 
 
DEVELOPMENTS IN MR  
MR using multiple instruments 
Recent decreases in genotyping costs and increases in the number of successful GWAS have 
enabled a large number of genetic variants associated with phenotypic traits to be discovered 
(17). This has resulted in the opportunity to extend the single variant approach typically used in 
MR to consider multiple genetic instruments. These instruments can be used either individually, 
taking independent genetic variants that each work through different biological pathways, or 
combined into a single allele score (18–20). An allele score is a weighted or unweighted sum of 
the number of ‘risk’ alleles across several genotypes associated with a given trait, where the 
weights are generally based on each genotype’s effect on the trait of interest (e.g. the SNP effects 
observed from GWAS). 
 
A key advantage of using multiple instruments is that it has the capacity to increase the statistical 
power of MR analyses. When each instrument independently explains variability in the exposure 
trait of interest, use of multiple instruments can increase the precision of IV estimates (18). This 
is important since MR analyses generally require very large sample sizes due to the small 
amount of variation in a trait typically explained by a single genetic variant.  
 
In addition, the multiple instrument approach provides opportunities to test IV assumptions in a 
way that is not possible in single instrument analyses (18). The validity of the IV assumptions 
underlying MR analyses can be affected by LD and pleiotropy. A multiple instrument approach 
can be used to assess their likely presence. Specifically, the IV estimates from multiple 
instruments can be compared. If each independent instrument predicts the same causal effect of 
the proxied-for environmentally modifiable risk factor, then it becomes much less plausible that 
confounding by pleiotropy or LD explains the associations, because the confounding would have 
to be acting in the same way for each independent instrument (21). However, if there is missing 
data on genetic variants, a multiple variants approach can potentially result in a diminished 
sample size because only individuals with complete data on all genotypes used in an allelic score 
can be included, thereby reducing the power of the study (18). Furthermore, there is also 
potential for increased bias in the IV estimator when weak instruments are used. This weak IV 
problem can be alleviated by combining the instruments into an allele score, although with some 
reduction in power (20). Multiple variant approaches have been applied in a numerous MR 
studies, including recent applications using allele scores for BMI (22,23), as well as multiple 
independent genetic instruments for iron (24) and LDL cholesterol (25).  
 
MR using summary statistics 
The existence of published information from GWAS, which typically report regression 
coefficients summarizing the associations of many genetic variants with various traits, has been 
suggested as a potentially powerful source of data for MR studies (26). Where a single genetic 
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variant is used as an IV, the estimate of the causal effect using summarized data can be 
calculated in a straightforward manner with ratios based on summary statistic regression 
coefficients (3,27,28). This has been successfully implemented, for example, using meta-analysis 
data from iron SNPs to demonstrate evidence of a potential protective effect of serum iron on 
risk of Parkinson disease (24). Summary statistic estimates based on the genotype association 
alone can also be used to infer causality, as illustrated by MR studies demonstrating a 
relationship between alcohol intake and increased blood pressure (29) and esophageal cancer 
(30). Methods using summarized data in the context of multiple variants have also recently been 
proposed (26). In addition, the integration of genetic association studies using meta-analysis for 
the genotype-exposure association and the genotype-outcome association have also been 
explored in relation to MR (31) and has particular relevance for increasing power in the context 
of summary statistic data. 
 
The use of summary statistics is somewhat limited by the fact that, as pointed out by others (26), 
the assumptions required for MR to be valid cannot be assessed as comprehensively as when 
using individual-level data. Furthermore, for multiple variant analyses using summary statistics, 
inflated precision has been observed when variants are in linkage disequilibrium (26). 
Nonetheless, while individual-level data should ideally be implemented in MR studies wherever 
possible, when such data are unavailable, the existence of accessible summarized data can 
facilitate valid IV analyses for single or multiple instruments MR.  
 
Two-sample MR 
In traditional MR, estimates are produced from a single dataset consisting of participants with 
information on the genetic variant, exposure and outcome. However, situations may arise where 
information on the exposure and the outcome are available in two different datasets. In this case 
it is possible to implement two-sample IV approaches with respect to MR using ratio-based 
estimates (32,33). This approach will be particularly relevant for exposure biomarkers that are 
expensive to obtain or biospecimens that are either not widely available or are difficult to 
measure.  
 
A subsetting approach may also be feasible where exposure data is only available in a subset of 
individuals in a given sample. The use of “sub-sample IV estimators” applied to MR has been 
shown to be effective when the IV is relatively strong (32). In addition, a “split-sample” 
approach might be considered where no known genetic instruments exist for the intermediate 
phenotype of interest or no relevant GWAS has been undertaken with respect to appropriate 
genetic instruments. In this case, one could potentially undertake both the GWAS to identify  
SNP instruments and the MR analysis in a single sample that has been divided into two or more 
subsamples (23). This ensures that the GWAS and the MR analysis are still carried out in 
different data subsets within the sample, in order to minimize potential bias (see the ‘Genome-
wide MR’ section in relation to overlapping samples bias).  
 
Bi-directional approach 
A bi-directional MR approach has recently been proposed and implemented with the aim of 
facilitating a particularly clear assessment of the causal direction of an observed association 
(14,34,35). This approach exploits the availability of two independent instruments that yield 
unconfounded estimates of causal effect. The direction of causality for an association between 
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two variables is assessed through the use of a genetic proxy for one variable and a separate 
genetic proxy for the second variable. Two MR analyses are undertaken, one for each of the 
genetic proxy variables.  
 
For example, to assess the direction of causality for an observed association between BMI and 
CRP, two MR analyses are performed. The first MR analysis associates BMI genetic variants 
with CRP, while the second MR analysis relates CRP genetic variants with BMI. If an 
association was observed in the first analysis, but not in the second analysis, this suggests that 
BMI causally affects CRP levels, and not the other way around. This bi-directional approach has 
been successfully implemented in several studies to interrogate the direction of causation for the 
associations between BMI with CRP (34,35), Vitamin D (36) and uric acid (37). 
 
Additional Extensions to MR 
Factorial MR. The concept of carrying out ‘factorial MR’ (1,14) refers to the suggestion that the 
MR framework could be applied to investigate combinations of risk factors that are potentially 
acting together to affect disease risk. For example, obesity and alcohol intake have been found to 
synergistically increase risk of liver disease, with multiplicative interactions observed (38,39). 
MR analyses could therefore be applied to generate effect estimates for co-occurring risk factors 
using combinations of genetic variants that each acts as a proxy for the relevant risk factor. 
 
Multi-phenotype MR. In addition to using MR for assessing risk factors with synergistic or 
combined effects, another related extension involves separating the independent effects of risk 
factors when multiple phenotypes are correlated with a particular SNP of interest or a set of 
SNPs. This multi-phenotype correlation poses problems for the MR framework since 
disentangling the SNP’s effects on one particular phenotype will be challenging. Thus attempts 
to address this issue have recently been implemented, in what has been termed multi-phenotype 
MR (14).To illustrate, LDL cholesterol, HDL cholesterol and triglycerides are strongly 
correlated with one another and genetic variants identified for triglycerides tend to also be related 
to LDL or HDL (40). Estimating an independent causal effect of triglycerides is therefore limited 
when using such variants in a traditional MR design. Recent MR studies have therefore 
attempted to separate out effects of the correlated lipids on risk of heart disease using approaches 
such as: (i) allele-score restrictions (excluding SNPs correlated with more than one lipid); (ii) 
sequential statistical adjustments of the IV analysis for non-target lipids; (iii) SNP-based 
regressions that correlate the target lipid SNP effect with the corresponding SNP effect for 
coronary artery disease, controlled for the SNPs effects on the non-target lipids using residuals 
(41,42). Broadly-speaking, regression-based approaches will, in principal, still be subject to the 
typical epidemiological concerns over attempting to attribute causality using statistical control 
for correlated variables (43,44). However, the multi-phenotype framework remains a promising 
area which is currently under development (14). 
 
Hypothesis-free approach. The increasing availability of high-throughput biological information 
is resulting in extremely large datasets of genotypic and phenotypic data. Such datasets lend 
themselves to the appealing possibility for a powerful hypothesis-free approach (21). In this way, 
one could effectively test the causality of extremely large numbers of phenotypic associations in 
a single study. There is promising evidence from genome-wide data, that at least screening for 
causal associations in this way could be successfully implemented (45). Hypothesis-free 
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approaches will be increasingly relevant as “omics” databases, with extraordinarily large 
numbers of new biomarkers, continue to proliferate. 
 
POTENTIAL MR APPLICATIONS USING ‘OMICS’ DATA 
There is much anticipation surrounding the prospects of ‘omics’ technologies, with high 
expectations that they may revolutionize the practice of epidemiology through advancing the 
tools for exposure and outcome measurements (46). Indeed, the recent explosion in availability 
of such ‘omics’ data, generating hundreds of thousands of genetic markers and hundreds or 
thousands of biological markers, presents exciting new opportunities for increasing causal 
biomedical knowledge through the implementation of MR. Here, we discuss three of these 
‘omics’ data sources (genome-wide genotype data, epigenetics, metabolomics) with respect to 
their potential future application in MR studies. 
 
Genome-wide Genotypes  
Within a short period of time, genome-wide association studies (GWAS) have successfully 
identified thousands of genetic variants robustly associated with complex traits/diseases (17). 
GWAS test individual single nucleotide polymorphisms (SNPs) covering the whole genome for 
their association with traits/diseases. This individual SNP association approach can identify 
specific loci affecting complex traits but it doesn’t exploit the true potential of the correlated 
structure of the data. For example, it has been shown with respect to human height that analyzing 
genome-wide SNP data simultaneously quadrupled the amount of variation explained (47), 
compared with that of the 180 height loci which reached genome-wide significant levels (48).  
 
The capacity of genome-wide SNPs to explain vastly more variation in traits begs the question as 
to whether issues with statistical power that frequently limit MR studies might potentially be 
addressed by utilizing more of the genome, for example, through the use of allele scores from 
genome-wide SNPs. Such allele scores are proxy measures for the trait of interest and, with 
adequate heritability, can therefore have strong relationships with the phenotypic trait. Indeed, 
genome-wide allele scores have been proposed for capturing larger amounts of phenotypic 
variation in traits in genetic association studies (49). 
 
It was recently demonstrated that the application of genome-wide allele scores can be used to 
index biological intermediates of disease outcomes, with promising applications for large-scale 
screening of causal associations between potentially vast numbers of biological factors and 
disease outcomes (45). However, systematic assessment of the validity of implementing genome-
wide allele scores in MR studies, is yet to be carried out. In particular, it should be noted that 
such genome-wide scores comprise variants that are data-derived, where over-fitting can occur, 
as opposed to the use of robustly associated variants that are generally applied in traditional 
single-SNP MR. Furthermore, there is some evidence that bias may occur with allelic scores 
incorporating genetic markers at less stringent p-value thresholds for associations (19).  
 
The extent of any potential pleiotropy will also require careful assessment.  Empirical studies 
suggest that common genetic variants are not typically related to the behavioral and socio-
economic factors that are considered to be important confounders in conventional observational 
studies (50) (although this does not necessarily hold true for detailed biological profiling, such as 
for lipoprotein subclasses (51)). In addition, there is some evidence that using certain allelic 
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scores based on all SNPs across the genome may result in pleiotropic associations being 
observed (45). Analogous to the suggestion that one could assess pleiotropy by using 
independent genetic instruments that are uncorrelated but proxy for the same phenotypic trait of 
interest (16), independent uncorrelated allele scores (such as scores constructed by chromosome 
number) could, similarly, be explored to assess pleiotropic effects in genome-wide analyses.   
 
To maximize power, identifying allele scores that capture the most variation in the intermediate 
phenotype will be advantageous. The nature of this will likely differ among traits and be 
dependent on factors such as the discovery GWAS sample size. For example, BMI allele scores 
with liberal thresholds for inclusion (i.e. including all SNPs, even those with very low p-values 
for association) explain more variation than allele scores comprised only of SNPs meeting the 
stringent p-value threshold for GWAS-level significance (45). In contrast, more stringent SNP p-
value thresholds are optimal for capturing most variation in LDL and CRP. In addition, weighted 
allele scores have been shown to be preferable to unweighted scores, at least in terms of 
statistical power (18,20).  
 
Finally, given the continually expanding size of GWAS consortia, it is increasingly possible that 
a given sample in which genome-wide allele scores are being constructed for analyses may also 
have been part of the GWAS study that generated the relevant SNP estimates used, for example, 
to weight the score. This will be problematic as biased estimates in the variance explained in a 
given trait arises when using allele scores that are constructed with SNP coefficients from a 
GWAS containing any of the same individuals being analyzed (49).  
 
In sum, important methodological issues will need to be addressed before the implementation of 
genome-wide scores to MR analyses, in particular the potential introduction of pleiotropy and the 
consideration of biases such as overlapping samples. However, the availability of accessible 
genome-wide data in increasingly large samples and the substantial increase in variation 
explained in phenotypic traits by genome-wide allele scores represent exciting opportunities for 
developing more powerful MR studies.  
 
Epigenetics 
Enthusiasm for epidemiological studies based on epigenetic data is gaining considerable 
momentum in light of its potential to yield new insights into disease etiology and to provide a 
mechanism for gene-environment interactions (52,53). The epigenome comprises 
environmentally induced biological modifications of DNA that have the ability to regulate gene 
expression. Intriguing associations have been observed between these epigenetic modifications 
and environmental factors such as diet, alcohol, smoking and inflammation (53) as well as with 
disease outcomes such as for heart disease, stroke and mortality (54), schizophrenia and bipolar 
disorder (55).  
 
However, while the primary hypothesis is that environmental factors influence the epigenome, 
which subsequently alters the regulation of gene expression and thus modulates disease risk, the 
evidence to support this is currently preliminary. Determining the causality of any observed 
epigenetic associations will be particularly challenging because epigenetic biomarkers are 
vulnerable to the typical confounders (age, sex, socioeconomic positions, diet, smoking etc.) that 
also afflict many other molecular biomarkers. This is because, while genotypes are fixed, the 
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epigenome is modified by environmental factors and will therefore be susceptible to the same 
problems of confounding and reverse causation as these environmental factors are (56).  
 
A “two-step MR” approach, designed to interrogate causal mediation, has been proposed to 
investigate the role of epigenetic modifications in mediating risk factor associations with disease 
outcomes (57). Whilst this two-step approach was initially described in the context of epigenetic 
data, it can in principle be extended to any association involving a mediating variable. In a two-
step MR, an initial IV analysis assesses the causal effect of an exposure on a mediator (e.g. an 
epigenetic marker), and a second IV analysis assesses the causal effect of the mediator on the 
disease outcome. For epigenetic markers, it has been shown that a genetic IV acting as a proxy 
for an exposure variable could be used to generate an unbiased estimate of the effect of the 
exposure on a measure of DNA methylation (an epigenetic marker) and in a second analysis, a 
genetic IV (specifically, a cis-variant) could be used as a proxy for the same DNA methylation 
measure and provide an estimate the effect of methylation on the disease outcome (57).  
 
Epigenetic MR is, however, still in its infancy and, as discussed elsewhere (57), is currently 
limited by several factors. Firstly, reported associations between environmental factors and both 
global and gene-specific DNA methylation are often modest in size.  Secondly, while DNA 
sequence is fixed, epigenetic patterns vary across different tissue types. As such, assessing 
tissue-specific epigenetic patterns will be important, since the association of an epigenetic 
marker with a phenotype or with a genetic variant will likely vary across tissue-types. While 
some tissue types are easily accessible (such as blood) others will be more challenging to obtain 
in samples sufficiently large for the implementation of this approach. Nonetheless, the 
implementation of epigenetic MR appears promising with MR already beginning to be applied to 
resolve issues of confounding and reverse causation with epigenetic measures. This can be seen 
for example with respect to assessing the effect of DNA methylation on postnatal growth (58) 
and body mass index (59,60). 
 
Metabolomics 
There is much interest in dissecting the role of the metabolome in health and disease. The 
availability of high throughput data, advances in data handling and processing as well as 
statistical tools may provide unprecedented insights into our understanding of complex diseases 
(61,62). The metabolome represents multiple metabolic pathways in systemic metabolism and 
includes, for example, lipoproteins, vitamin and cofactor levels, lipids, amino acids and other 
small molecules involved in glycolysis, the citric acid cycle and the urea cycle. Metabolites are 
produced endogenously as a result of chemical processes as well as from exogenous sources such 
diet and drugs. Circulating metabolites have been implicated in disorders of the metabolic and 
cardiovascular systems and have also proved useful in the prediction of cardiometabolic disease 
(63). However, the current understanding of the metabolome in disease pathogenesis is 
incomplete. 
 
Recent technological developments in the analytic platforms - proton nuclear magnetic 
resonance (NMR) and mass spectroscopy - have enabled hundreds to thousands of metabolites to 
be measured in a single procedure. Given the relationship of metabolites with environmental 
exposures, there is therefore considerable potential for powerful epidemiological studies (62). 
Furthermore, since many metabolites have substantial heritability and robust genetic variant 
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associations that have already been identified (61,64), MR represents an ideal framework for 
investigating the potential causal pathways involving metabolites and disease outcomes. In 
particular, metabolites may act as mediators between an exposure and disease outcome. 
 
Given the potentially serious biases that can occur in mediation analysis using traditional 
epidemiological approaches, as a result of unmeasured confounders and measurement error (65–
67), the two-step MR approach for mediation, outlined above, will be a particularly useful 
framework to consider causal mediating pathways involving metabolites since it does not rely on 
statistical adjustments to estimate the mediation effect, as is inherent in the former approaches 
(14). In applying two-step MR to metabolomic mediators, two IV analyses would be applied to 
assess the effect of an exposure on a particular metabolite, followed by an assessment of the 
impact of the respective metabolite on a disease outcome of interest.  
 
Difficulties with data harmonization are an existing concern with metabolomic data originating 
across different studies, with either different analytic platforms being utilized or varying methods 
to identify and quantify metabolites (62). Obtaining reliable approaches for synthesizing 
metabolic data among studies is likely to be particularly relevant for implementing MR to 
metabolomics data, given that MR generally requires very large samples to attain sufficient 
statistical power.  
 
CONCLUSIONS 
There is now a range of emerging developments in MR that are extending the established single-
SNP approach to incorporate larger amounts of biological information and test different 
hypotheses. These have the potential to both address some of the existing limitations of 
conventional single-SNP MR as well as to answer new and exciting questions involving the 
increasingly available ‘omics’ data (such as genome-wide genotype data, epigenetics, 
metabolomics). Several key issues will require consideration, ranging from biases in the 
construction of genome-wide allele scores, the availability of tissue specific epigenetic patterns 
and limitations to data harmonization with metabolomics measures. However, with these novel 
and emerging applications of the MR framework, powerful studies and an unprecedented range 
of biomedical questions in the ‘omics’ era could potentially be explored.  
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Table 1 Examples of Mendelian randomization studies 
Exposure Disease Findings 
Alcohol intake Hypertension 
 
Esophageal cancer  
 
Head and neck cancer 
Alcohol consumption increases blood pressure (29) 
 
Alcohol consumption increases risk of esophageal cancer (30) 
 
Alcohol consumption increases risk of head and neck cancer (68) 
 
Milk calcium intake Bone density and fractures 
 
Lower milk calcium intake reduces bone mineral density and increases risk of bone 
fractures (69) 
 
Tobacco smoking 
 
Cardiovascular risk factors Smoking lowers BMI, waist and hip circumference, estimated glomerular filtration 
rate and resting heart rate. Smoking is associated with, but does not causally affect 
waist-hip ratio, diastolic blood pressure, CRP, serum lipid or glucose levels  (70) 
 
BMI Uric acid 
 
Cardiometabolic  
traits and events 
 
 
Vitamin D 
 
 
Gallstone disease 
Elevated BMI increases risk of uric-acid related conditions (37) 
 
Elevated BMI increases fasting glucose, fasting insulin, IL6, systolic blood 
pressure and reduces HDL and LDL cholesterol. Elevated BMI increases risk of 
type 2 diabetes but is not causally related to risk of CHD or stroke (22) 
 
Observational associations between obesity and vitamin D deficiency are driven by 
causal effects of higher BMI reducing vitamin D levels (36) 
 
Elevated BMI increases risk of gallstone disease (71) 
 
CRP Cardiometabolic traits 
 
 
CHD 
 
Elevated CRP is associated with, but does not causally affect, BMI, blood pressure, 
waist-to-hip ratio, HDL cholesterol, triglycerides, insulin resistance (72) 
 
Elevated CRP is associated with, but does not causally affect, risk of CHD (73) 
 
IL6 CHD Higher IL-6 activity increases risk of CHD (74,75) 
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Uric acid 
 
IHD and blood pressure Higher uric acid levels is associated with, but does not causally affect, risk of IHD 
or high blood pressure (37) 
 
Serum iron 
 
Parkinson’s Disease Increased iron levels reduce risk of Parkinson’s Disease (24) 
Triglycerides CHD and CAD Elevated triglycerides increase risk of CHD and CAD (41,42,76) 
 
LDL cholesterol CHD Lower LDL cholesterol reduces risk of CHD (25) 
 
HDL cholesterol  Myocardial infarction  Higher HDL cholesterol is associated with, but does not causally affect, risk of 
myocardial infarction (77) 
 
 
CRP C-reactive protein, CAD coronary artery disease, CHD coronary heart disease, HDL high-density lipoprotein, IHD ischaemic heart disease, LDL lowdensity lipoprotein 
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G 
Genetic 
instrument 
E 
Exposure 
D 
Disease outcome 
U 
Unmeasured 
confounders 
G 
e.g. FTO 
variant 
U 
 e.g. socio-economic factors 
E 
e.g. body mass index 
Figure 1 Mendelian Randomization. 
 
A genetic instrumental variable [G] acts as a proxy measure for an environmental 
exposure [E], that is postulated to influence disease [D], where G is independent of 
measured and unmeasured confounders [U]. G only influences D if a causal 
association exists between E and D. For example, the extent to which body mass 
index (BMI) causally affects blood pressure (BP), can be quantified using a genetic 
variant associated with BMI, such as FTO.  This variant, which should be unrelated to 
the typical confounders, will be associated with blood pressure (BP), if there is a 
causal relationship of BMI on BP. 
D 
e.g. blood pressure 
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